CAMBRIDGE, MASSACHUSETTS–(Marketwired – Oct. 27, 2016) – VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) (“VBI”) is scheduled to present at the Keystone Symposia on Translational Vaccinology for Global Health on Thursday, October 27, 2016 at 7:00 PM BST (2:00 PM ET). The event is being held at the Park Plaza Riverbank London in the United Kingdom.
During the poster presentation, Bivalent eVLP Expression of Envelope and NS1 Antigens as a Vaccine Against Zika, Dr. Marc Kirchmeier, Ph.D., VBI’s Vice President of Formulation Development, will provide an overview of VBI’s eVLP Platform and will summarize recent developments in VBI’s Zika Vaccine Program.
“Virus-like particle (VLP) technology is a proven vaccine approach and the basis for several licensed human vaccines,” said Dr. Kirchmeier. “VBI is applying its own eVLP technology in the development of a novel vaccine candidate to prevent Zika virus infection. Early immunogenicity testing of our Zika vaccine candidate demonstrates our ability to induce high antibody titers, which some research has shown to be a correlate of protection.”
The Translational Vaccinology for Global Health session is part of the Keystone Symposia Global Health Series, which is supported by the Bill & Melinda Gates Foundation. For more information, visit: http://www.keystonesymposia.org/16S1.
Event Details
- Event: Keystone Symposia on Translational Vaccinology for Global Health
- Date: Thursday, October 27, 2016
- Time: 7:00 PM BST (2:00 PM ET)
- Location: Park Plaza Riverbank London in London, United Kingdom
- Event Website: http://www.keystonesymposia.org/16S1
About VBI Vaccines Inc.
VBI Vaccines Inc. (“VBI”) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI’s first marketed product is Sci-B-Vac™, a hepatitis B (“HBV”) vaccine that mimics all three viral surface antigens of the hepatitis B virus; Sci-B-Vacis approved for use in Israel and 14 other countries. VBI’s eVLP Platform technology allows for the development of enveloped (“e”) virus-like particle (“VLP”) vaccines that closely mimic the target virus to elicit a potent immune response. VBI is advancing a pipeline of eVLP vaccines, with lead programs in cytomegalovirus (“CMV”) and glioblastoma multiforme (“GBM”). VBI is also advancing its LPV™ Thermostability Platform, a proprietary formulation and process that allows vaccines and biologics to preserve stability, potency, and safety. VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel.
- Website Home: http://www.vbivaccines.com/
- News and Insights: http://www.vbivaccines.com/wire/
- Investors: http://www.vbivaccines.com/investors/
Cautionary Statement on Forward-looking Information
Certain statements in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation (collectively, “forward-looking statements”) that may not be based on historical fact, but instead relate to future events, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. All statements other than statements of historical fact included in this release are forward-looking statements, including statements regarding: the potential for safer and more potent vaccine candidates, including a Zika candidate.
Such forward-looking statements are based on a number of assumptions, including assumptions regarding the successful development and/or commercialization of the company’s products, including the receipt of necessary regulatory approvals; general economic conditions; that the parties’ respective businesses are able to operate as anticipated without interruptions; competitive conditions; and changes in applicable laws, rules and regulations.
Although management believes that the assumptions made and expectations represented by such statements are reasonable, there can be no assurance that a forward-looking statement contained herein will prove to be accurate. Actual results and developments may differ materially from those expressed or implied by the forward-looking statements contained herein and even if such actual results and developments are realized or substantially realized, there can be no assurance that they will have the expected consequences or effects. Factors which could cause actual results to differ materially from current expectations include: the failure to successfully develop or commercialize the company’s products; adverse changes in general economic conditions or applicable laws, rules and regulations; and other factors detailed from time to time in the company’s reports filed with the U.S Securities and Exchange Commission and the Canadian Securities Commissions.
Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on the company’s current expectations, and the company undertakes no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.
Perri Maduri
Communications Executive
(617) 830-3031 x124
ir@vbivaccines.com
VBI Investor Contact
Nell Beattie
Director, Corporate Development and Investor Relations
(617) 830-3031 x128
nbeattie@vbivaccines.com